Treatment of multiple sclerosis with natalizumab: experiences from a real-life cohort over 15 years

被引：0
|
作者：
Auer, M. [1 ]
Zinganell, A. [1 ]
Hegen, H. [1 ]
Bsteh, G. [2 ]
Di Pauli, F. [1 ]
Berek, K. [1 ]
Fava, E. [1 ]
Wurth, S. [3 ]
Berger, T. [2 ]
Deisenhammer, F. [1 ]
机构：
[1] Med Univ Innsbruck, Innsbruck, Austria
[2] Med Univ Vienna, Vienna, Austria
[3] Med Univ Graz, Graz, Austria
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P693
引用
下载
收藏
页码：588 / 588
页数：1
相关论文
共 50 条
  • [21] Real-life clinical practice studies in multiple sclerosis
    Costa-Frossard, Lucienne
    FARMACIA HOSPITALARIA, 2021, 45 (02) : 51 - 52
  • [22] Real-Life Outcome in Multiple Sclerosis in the Czech Republic
    Kobelt, Gisela
    Joensson, Linus
    Pavelcova, Miluse
    Havrdova, Eva Kubala
    MULTIPLE SCLEROSIS INTERNATIONAL, 2019, 2019
  • [23] Relapse associated worsening in a real-life Multiple Sclerosis cohort: the role of age and pyramidal phenotype
    D'Amico, E.
    Galgani, S.
    Bellantonio, P.
    Zaffaroni, M.
    Borriello, G.
    Inglese, M.
    Romano, S.
    Conte, A.
    Patti, F.
    Avolio, C.
    Trojano, M.
    Zanghi, A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 998 - 999
  • [24] Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort
    Hacohen, Yael
    Brownlee, Wallace
    Mankad, Kshitij
    Chong, Wui K. 'Kling'
    Thompson, Alan
    Lim, Ming
    Wassmer, Evangeline
    Hemingway, Cheryl
    Barkhof, Frederik
    Ciccarelli, Olga
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (11) : 1372 - 1380
  • [25] "Real-life" outcomes in a monocentric cohort of highly active multiple sclerosis patients treated with alemtuzumab
    Moiola, L.
    Ferreira, J.
    Robotti, M.
    Romeo, M.
    Sangalli, F.
    Guerrieri, S.
    Pisa, M.
    Esposito, F.
    Martinelli, V.
    Comi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 339 - 340
  • [26] Real life use of natalizumab and fingolimod - data from the nation-wide Austrian Multiple Sclerosis Treatment Registry
    Guger, M.
    Enzinger, C.
    Leutmezer, F.
    Kraus, J.
    Berger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 315 - 316
  • [27] Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis. Results from the TYNERGY Trial; A Study in the Real Life Setting
    Svenningsson, Anders
    Falk, Eva
    Celius, Elisabeth G.
    Fuchs, Siegrid
    Schreiber, Karen
    Berko, Sara
    Sun, Jennifer
    Penner, Iris-Katharina
    PLOS ONE, 2013, 8 (03):
  • [28] Dimethyl fumarate and teriflunomide for multiple sclerosis in a real-life setting: a French retrospective cohort study
    Conde, S.
    Moisset, X.
    Pereira, B.
    Zuel, M.
    Colamarino, R.
    Maillet-Vioud, M.
    Lauxerois, M.
    Taithe, F.
    Clavelou, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 (03) : 460 - 467
  • [29] Clinical follow-up of 411 patients with relapsing and progressive multiple sclerosis 10 years after discontinuing mitoxantrone treatment: a real-life cohort study
    Chartier, N.
    Epstein, J.
    Soudant, M.
    Dahan, C.
    Michaud, M.
    Pittion-Vouyovitch, S.
    Guillemin, F.
    Debouverie, M.
    Mathey, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 (12) : 1439 - 1445
  • [30] Multiple Sclerosis Treatment with Natalizumab: Analysis of a Hospital-Based Cohort
    Carvalho, Ana Teresa
    Abreu, Pedro
    Sa, Maria Jose
    ACTA MEDICA PORTUGUESA, 2014, 27 (04): : 437 - 443
12345